-
3 Specialty Export Formulations, Cardiac and CNS Leader and Contract Injectables Stocks With a Strong Future Roadmap: Rubicon Research, Torrent Pharmaceuticals and Gland Pharma
- October 22, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
No Comments
Pharma Exports and Chronic Care Stocks with a strong future roadmap: Rubicon Research, Torrent Pharmaceuticals and Gland Pharma. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.
-
3 Custom API Manufacturing, Specialty Formulations and Acute Therapy Brands Stocks With a Strong Future Roadmap: Neuland Laboratories, Rubicon Research and Alkem Laboratories
- October 22, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
API and Formulation Growth Stocks with a strong future roadmap: Neuland Laboratories, Rubicon Research and Alkem Laboratories. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.
-
3 Contract Research Partner, Specialty Formulations and Branded Generics Stocks With a Strong Future Roadmap: Sai Life Sciences, Rubicon Research and Ajanta Pharma
- October 22, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Specialty Pharma and Research Services Stocks with a strong future roadmap: Sai Life Sciences, Rubicon Research and Ajanta Pharma. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.
-
3 Anti-Retroviral Ingredients, Paracetamol Dosages and Specialty Formulations Stocks With a Strong Future Roadmap: Laurus Labs, Granules India and Rubicon Research
- October 21, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
API and Formulation Maker Stocks with a strong future roadmap: Laurus Labs, Granules India and Rubicon Research. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Newly Listed Pharma Stocks With a Strong Future Roadmap: Corona Remedies, Rubicon Research and Kwality Pharmaceuticals
- October 7, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Corona Remedies, Rubicon Research and Kwality Pharmaceuticals compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.
-
This Specialty Dosage Stock Rises 116% in 6 Months: What Is Driving the Re-Rating?
- September 23, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
One US-focused formulation maker doubled in six months on four straight earnings beats and a clean USFDA record. Here is what drove the move and what could stop it.